Plain-English translation of NCT05958719 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a treatment combination called plus three other chemotherapy drugs (, , and ) can help patients with a newly diagnosed rare blood cancer called nodal T-follicular helper cell lymphoma. Researchers believe this four-drug combination may work better and cause fewer side effects than standard treatments currently available. If the medication works well, you may continue with additional treatment, including possibly a stem cell transplant, followed by long-term maintenance therapy.
This rare type of lymphoma is difficult to treat with standard approaches, and patients often do not respond well to conventional therapies. Researchers hope this new medication combination will help more patients achieve remission and improve their chances of long-term survival.
You likely qualify if…
You likely don't qualify if…
You would receive the four-drug combination as inpatient or outpatient treatment over four cycles (typically weeks or months, depending on the protocol). After four cycles, doctors will scan your body using PET-CT imaging to see how well the treatment is working. Depending on your response, you may receive two more cycles of the same treatment, and if eligible, you could undergo a stem cell transplant. After that, you would take a single maintenance medication () twice weekly by mouth for 24 months. Throughout the trial, you'll have regular blood tests and follow-up visits to monitor your health and any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China